Trial Profile
TMC125-TiDP2-C238: A Randomized, Exploratory, Open-Label 48-Week Trial to Investigate the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of Etravirine (ETR) in Combination With Ritonavir-Boosted Atazanavir (ATV/Rtv) and 1 NRTI in Treatment-Experienced HIV-1 Infected Subjects.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Etravirine (Primary) ; Atazanavir/ritonavir; Nucleoside reverse transcriptase inhibitors; Tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms TEACH
- Sponsors Janssen R&D Ireland
- 30 Jun 2013 Results presented at the 7th International AIDS Society Conference on HIV Pathogenesis and Treatment.
- 07 Aug 2012 Actual patient number changed from 53 to 52 as reported by ClinicalTrials.gov.
- 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.